Nikhil Shiva

Nikhil Shiva is a corporate associate in Goodwin's Life Sciences group. Nikhil advises life sciences, healthcare, and technology companies, as well as the investors who back them, across the corporate life cycle, including company formations, venture capital financings, mergers & acquisitions, capital markets transactions, initial public offerings (IPOs), public company reporting, and corporate governance matters. He joined Goodwin in 2023.

Nikhil represents emerging companies from formation through growth-stage financings and strategic exits and has helped launch more than a dozen new life sciences companies. He also advises public companies on SEC reporting and compliance matters, including Forms 10-K and 10-Q, proxy statements, at-the-market offerings, and Section 16 reporting, and represents leading venture capital and institutional investors in their portfolio investments.

As a first-year associate, Nikhil was on secondment at a leading life sciences investment fund as part of Goodwin’s Client Immersion Program.

• Kardigan in its $254 million Series B financing and $460 million IPO
• Parabilis Medicines in its $305 million Series F financing, $770.5 million IPO, and $75 million private placement
• Freenome in its $330 million deSPAC with Perceptive Capital Solutions Corp.
• Centessa Pharmaceuticals in its $250 million follow-on offering and its acquisition by Eli Lilly and Company
• Blueprint Medicines in its sale to Sanofi
• Dren Bio in connection with its sale of DR-0201 to Sanofi
• Wellington Management in its portfolio company investments
• RA Capital in its portfolio company investments
• InTandem Capital in its strategic equity investment in Healthfuse
• Datavolo in its sale to Snowflake
• Day Zero Diagnostics in its asset sale to bioMérieux
• PennyMac Financial Services in connection with its private offering of $650 million of senior notes
• Radial in its $50 million Series A financing

Goodwin Pro Bono Star, 2025

Co-Author, “CRISPR-SKIP: programmable gene splicing with single base editors,” Genome Biol 19, 107, 2018